Literature DB >> 7888055

Reduced size liver transplantation, split liver transplantation, and living related liver transplantation in relation to the donor organ shortage.

M J Slooff1.   

Abstract

Because of the shortage of cadaveric donors, three techniques of partial liver grafting have been developed. These techniques are placed in perspective in relation to the organ shortage. Reduced size liver transplantation (RSLTx) is widely used and has results comparable to those from whole liver grafting. However, this technique, while benefitting pediatric patients, reduces the adult donor liver pool. It also makes inefficient use of an available adult donor liver. In split liver transplantation (SPLTx), the whole liver is used after bipartition for two recipients. The results are comparable to those of RSLTx. The problem with SPLTx is that it is a very demanding technique applied only in centers with extensive experience with liver resection and reduction. Living related liver transplantation (LRLTx) yields excellent results; however, it places an otherwise healthy person at risk. It is argued that instead of performing risky operations on healthy persons, the health authorities should take specific measures to alleviate the organ shortage. In the meantime, SPLTx should be developed further because of its optimal use of donor tissue. As for LRLTx, its excellent results and the present shortage of size-matched pediatric liver donors justify its use, at least for now.

Entities:  

Mesh:

Year:  1995        PMID: 7888055     DOI: 10.1007/bf00366715

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  9 in total

1.  Effects of ischemia-reperfusion on hepatic glutathione and plasmatic markers of graft function during in situ split-liver transplantation in adult recipients.

Authors:  G Santori; E Andorno; I Fontana; D Cottalasso; U Valente
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 2.  Split-liver transplantation. The Paul Brousse policy.

Authors:  D Azoulay; I Astarcioglu; H Bismuth; D Castaing; P Majno; R Adam; M Johann
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

3.  Split-liver transplantation for two adult recipients: feasibility and long-term outcomes.

Authors:  D Azoulay; D Castaing; R Adam; E Savier; V Delvart; V Karam; B Y Ming; M Dannaoui; J Krissat; H Bismuth
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

4.  Trends in brain-dead organ donor characteristics: a 13-year analysis.

Authors:  Mazen Hassanain; Eve Simoneau; Suhail A Doi; Murad Aljiffry; Abdulla Aloraini; Ahmad Madkhali; Peter Metrakos
Journal:  Can J Surg       Date:  2016-06       Impact factor: 2.089

5.  Split liver transplantation: King's College Hospital experience.

Authors:  M Rela; V Vougas; P Muiesan; H Vilca-Melendez; V Smyrniotis; P Gibbs; J Karani; R Williams; N Heaton
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

6.  Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients.

Authors:  R M Ghobrial; H Yersiz; D G Farmer; F Amersi; J Goss; P Chen; S Dawson; S Lerner; N Nissen; D Imagawa; S Colquhoun; W Arnout; S V McDiarmid; R W Busuttil
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

Review 7.  In situ splitting of cadaveric livers. The ultimate expansion of a limited donor pool.

Authors:  X Rogiers; M Malagó; K Gawad; K W Jauch; M Olausson; W T Knoefel; M Gundlach; A Bassas; L Fischer; M Sterneck; M Burdelski; C E Broelsch
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.

Authors:  László Kóbori; Krisztina Kõhalmy; Pálma Porrogi; Enikõ Sárváry; Zsuzsa Gerlei; János Fazakas; Péter Nagy; Jenõ Járay; Katalin Monostory
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

9.  Split liver transplantation.

Authors:  D C Broering; J Schulte am Esch; L Fischer; X Rogiers
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.